Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|July 27, 2005
Microm Microtech France in drive for growth after management buy-out
Co-founder of BioMedical Diagnostics, Daniel Pierron, invests alongside Sofimac and BNP Paribas Développement
Advertisement
Francheville, France – July 27, 2005 – Microm Microtech France (MM-F), a specialized distributor of leading edge diagnostics products for the healthcare market, today announces its strategy for growth after a leveraged management buy-out led by Daniel Pierron, one of the co-founders of diagnostics firm, BMD. Sofimac and BNP Paribas Dveloppement supported the buy-out.
MM-F specializes in enabling laboratories involved in human histology and cytopathology (study of disease changes within individual cells or cell types) to analyze cell or tissue samples taken from humans, and diagnose different diseases using sophisticated techniques. Some 98 per cent of cancers are diagnosed using these methods.
In bringing the latest diagnostic tools to its customers in hospitals, clinics and research labs, MM-F offers a range of products including macroscopy, (equiping rooms for macroscopy and autopsy), and immuno-histochemistry (the process of detection of antigens in tissue using antibodies), as well as various instrumentation, reagent and consumable products. It has a leading position on the market for microtomy (specimen preparation) and has an exclusive licence to distribute the products of Microm GmbH (Germany), the leading manufacturer of these devices.
Sales in the year ending September 2004 reached EUR5.2 million in a market representing some EUR200 million annually in Europe. The company sees significant growth in the markets with which it is associated in particular in immuno-histochemistry. MM-F believes it holds third position in the immuno-histochemistry market in France. It has invested significantly in this field and expects it to be one of the main planks of its success.
MM-F will also build on its competitive advantage in having a wide variety of products available for its customers in France, North Africa and Cambodia. The company services about 1,100 customers spread equally across the public and private sectors. It will maintain a strong team of field sales personnel, which currently comprise seven sales and three product managers as well as customer, training and after-sales support teams.
"MM-F holds an excellent position in the supply of advanced diagnostic products, and our strategy will be to grow our market by making sure we offer our customers a wide range of tools based on the latest technological advances," said Daniel Pierron, CEO of MM-F.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5